WYMM Tour: Perth

March 14, 2024, 2:00 PM - 5:00 PM
Perth, Australia

WYMM Tour: Perth

14 March 2024, 10:00 - 17:00 - Perth, Australia

Generate ultra-rich data for answers with impact.

Who says you can’t see it all? With a comprehensive view of structural variants and methylation, nanopore technology powers the bigger and bolder research questions you’ve always wanted to ask.​​

Join us on Thursday 14th March 2024 in Perth to hear from local experts who are breaking new ground in human genomics, using nanopore technology.​​​

What you're missing matters. Stay on top of what's next.​

Aside from talks ranging from human genomics for rare disease, to sequencing for cancer research, the full-day agenda will include networking breaks, Q&A, product displays, and opportunities to engage with your peers and nanopore experts.

Please note that this is an in-person event.

There is no delegate fee for this event, but registration is required. Lunch and refreshments will be provided. Your place at this event will be confirmed via email from events@nanoporetech.com.

Register

Agenda

Agenda

Time

Agenda (subject to change)

Speaker

10:00 — 10:30 am

Registration

10:30 — 10:40 am ​

Welcome

Ross Napoli, Oxford Nanopore Technologies

10:40 — 11:05 am ​

Estimating tumour fraction in cfDNA with nanopore methylation sequencing

Rodrigo Carlessi, Curtin Health Innovation Research Institute (CHIRI)

11:05 — 11:30 am ​

Our 9-month odyssey into the world of Oxford Nanopore: From recalcitrant fungi genome to polyploid plant RNA to amplicon sequencing

Fatima Naim, Curtin University

11:30 — 11:55 am ​

Characterising multiple types of variation of SVA retrotransposons using nanopore sequencing

Sulev Koks, Murdoch University

11:55 am — 12:20 pm ​

The utility of Oxford Nanopore Technologies in neurogenetic disease research, and future applications in diagnostics

Carolin Scriba, Harry Perkins Institute of Medical Research

12:20 — 1:20 pm ​

Lunch

1:20 — 1:45 pm

Revolutionising high resolution HLA Genotyping for transplantation assessment: Validation, implementation and challenges of Oxford Nanopore Technologies' Q20+ sequencing

Dianne De Santis, PathWest, Fiona Stanley Hospital

1:45 — 2:10 pm

Towards telomere-to-telomere fish genomes with Oxford Nanopore Technologies gap-filling

Richard Edwards, University of Western Australia

2:10 — 2:35 pm

Rapid amplicon assays - research and development to support plant biosecurity and diagnostics

Monica Kehoe, Department of Primary Industries and Regional Development WA

2:35 — 3:05 pm

Break

3:05 — 3:30 pm

Using long-read sequencing to characterise antimicrobial resistant bacteria for bacteriophage therapy

Samuel Montgomery, Telethon Kids Institute

3:30 — 3:55 pm​

Updates from Oxford Nanopore Technologies

Simon Dunbar, Oxford Nanopore Technologies

3:55 — 4:00 pm

Closing

Ross Napoli, Oxford Nanopore Technologies

4:00 — 5:00 pm

Social mixer

Speakers

picture of Rodrigo Carlessi

Estimating tumour fraction in cfDNA with nanopore methylation sequencing

Rodrigo Carlessi, Curtin Health Innovation Research Institute (CHIRI)

Dr Rodrigo Carlessi is a Cancer Council of Western Australia (CCWA) Postdoctoral Fellow. He leads th...

picture of Fatima Naim

Our 9-month odyssey into the world of Oxford Nanopore: From recalcitrant fungi genome to polyploid plant RNA to amplicon sequencing

Fatima Naim, Curtin University

Dr Fatima Naim is a senior research fellow at the Centre for Crop and Disease Management, at Curtin ...

picture of Sulev Koks

Characterising multiple types of variation of SVA retrotransposons using nanopore sequencing

Sulev Koks, Murdoch University

Prof Sulev Koks (MD, PhD, FRCPA) is a genomic pathologist with dual MD and PhD degrees, enabling him...

picture of Carolin Scriba

The utility of Oxford Nanopore Technologies in neurogenetic disease research, and future applications in diagnostics

Carolin Scriba, Harry Perkins Institute of Medical Research

I am a final year PhD Student working in the Rare Disease Genetics and Functional Genomic Group at t...

picture of Dianne De Santis

Revolutionising high resolution HLA genotyping for transplantation assessment: Validation, implementation and challenges of Oxford Nanopore Technologies' Q20+ sequencing

Dianne De Santis, PathWest, Fiona Stanley Hospital

Dr. Dianne De Santis is a Clinical Scientist at the Department of Clinical Immunology, PathWest, Fio...

picture of Richard Edwards

Towards telomere-to-telomere fish genomes with Oxford Nanopore Technologies gap-filling

Richard Edwards, University of Western Australia

Rich Edwards is a Principal Research Fellow and Academic Lead for the Minderoo OceanOmics Centre at ...

picture of Monica Kehoe

Rapid amplicon assays - research and development to support plant biosecurity and diagnostics

Monica Kehoe, Department of Primary Industries and Regional Development WA

Dr Monica Kehoe is a Plant Virologist and Molecular Plant Pathologist working for DPIRD in WA, as pa...

picture of Samuel Montgomery

Using long-read sequencing to characterise antimicrobial resistant bacteria for bacteriophage therapy

Samuel Montgomery, Telethon Kids Institute

Dr Montgomery is a senior research officer at Telethon Kids Institute. Since the onset of the COVID-...